Peptide · Fact sheet
Elamipretide
Also known as Forzinity · SS-31 · MTP-131 · Bendavia
Elamipretide is FDA approved only as Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. That approval does not establish a general mitochondrial, energy, anti-aging, or muscle-performance therapy.
What is Elamipretide?
Elamipretide is a small manufactured peptide that binds cardiolipin, a lipid in the inner mitochondrial membrane.
Forzinity received accelerated approval based on improved knee-extensor muscle strength, an intermediate endpoint considered reasonably likely to predict clinical benefit.
Benefits & claims
It is the first FDA-approved treatment for Barth syndrome and one of the clearest examples of a mitochondria-targeting peptide reaching regulatory approval.
Broader mitochondrial-disease, heart, eye, fatigue, and healthy-aging claims remain separate research questions; a Phase 3 primary mitochondrial myopathy trial did not meet its primary endpoints.
What the evidence supports
- The approval program observed improvement in knee-extensor muscle strength in a small group with Barth syndrome.
- The larger MMPOWER-3 trial in primary mitochondrial myopathy did not show benefit over placebo for walking distance or fatigue at 24 weeks.
Research areas
- Barth syndrome
- Primary mitochondrial myopathy
- Mitochondrial function and muscle energetics
- Heart and eye disorders in clinical research
- Other mitochondrial diseases and genetically defined mitochondrial myopathies
- Cardiac, ophthalmic, and muscle-function outcomes outside the approved indication
Dosage & frequency
Product-specific label informationForzinity has a labeled daily regimen for Barth syndrome in patients who weigh at least 30 kg. This approval does not establish treatment for general mitochondrial fatigue or aging.
Forzinity
Adults and pediatric patients with Barth syndrome weighing at least 30 kg
- Amount
- 40 mg
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Accelerated approval; adult severe renal impairment changes the amount.
Forzinity: renal adjustment
Adults with eGFR below 30 mL/min/1.73 m², not on dialysis
- Amount
- 20 mg
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
This adjustment is not established for pediatric renal impairment.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Elamipretide, SS-31, and MTP-131 name the same investigational lineage; the approved Forzinity formulation and indication matter.
Interactions & precautions
- The label reports in-vitro MATE1 inhibition; its limited interaction studies do not establish compatibility with every mitochondrial supplement or medicine.
What is still unresolved
- Benefits beyond the approved Barth syndrome population remain investigational.
Side effects & risks
- The current label identifies injection-site reactions as the most common adverse reactions.
- The formulation contains benzyl alcohol and carries a warning against use in neonates.
- Evidence from a small rare-disease population cannot characterize every uncommon or long-term harm.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceThe approved claim rests on a very small rare-disease program and an intermediate endpoint. Evidence should not be generalized to other mitochondrial disorders or consumer performance goals, especially because MMPOWER-3 was negative on its primary endpoints.
Studies
Registered post-marketing confirmatory trial for elamipretide in genetically confirmed Barth syndrome.
Phase 3 trial that did not meet its primary walking-distance or fatigue endpoints in primary mitochondrial myopathy.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| MMPOWER-3 Genetically confirmed primary mitochondrial myopathy 218 participants (actual) Randomized placebo-controlled trial; human | Elamipretide versus Placebo 24 weeks Primary: Six-minute walking distance and disease-specific fatigue score Phase: Phase 3 | Neither primary endpoint was met. Walking-distance difference −3.2 m; 95% CI −18.7 to 12.3. Cannot tell us: Primary mitochondrial myopathy is not interchangeable with the approved Barth syndrome population. Safety, uncertainty, and source detailsMost reported events were mild or moderate; this does not establish safety for unrelated uses. Limited to the studied population, formulation and follow-up. Funding/conflicts: Author disclosures include industry grants, consulting and sponsor employees; see full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Why does Barth syndrome approval not establish benefit in all mitochondrial diseases?
Accelerated approval has a narrow Barth syndrome scope; MMPOWER-3 studied a different population and missed its primary endpoints.
Limit: Knee-strength surrogate evidence does not remove the need to confirm patient benefit.
Check the sources: MMPOWER-3: elamipretide in primary mitochondrial myopathy (checked 2026-09-18) · FDA accelerated approval: Forzinity for Barth syndrome (checked 2026-09-18)
What is approved, and for whom?
United States records selected for the questions above; not a complete label or a worldwide approval inventory.
Forzinity: Barth syndrome
Subcutaneous injection · Patients with Barth syndrome weighing at least 30 kg
accelerated approval — Confirmatory evidence of patient benefit is required. This is not approval for primary mitochondrial myopathy generally.
Exact linked source and stated indication only; not an exhaustive regulatory search.
Read the original source · Source checked: 2026-09-18 · Decision: 2025-09-19
Compare research questions · Submit a source-based correction
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
More perceived energy and stamina
In an ME/CFS discussion, a commenter reported better energy, recovery and stamina with SS-31. They also reported MOTS-c exposure and perceived improvement when both were used.
Amount, frequency, route and duration could not be confirmed for this account.
Product identity and clinical outcomes were not verified. The combined experience does not establish benefit in ME/CFS or describe the approved Forzinity product.
Read the energy accountNo noticeable improvement in a contrasting account
A different commenter in a long-COVID discussion described trying SS-31 without noticing an effect, despite hoping for an energy improvement.
Amount, frequency, route and duration could not be confirmed for this account.
The source described an unverified research product, not confirmed Forzinity treatment. Diagnosis, duration and outcomes were not independently checked.
Read the no-improvement accountEndurance: reported experiences
More perceived energy and stamina
In an ME/CFS discussion, a commenter reported better energy, recovery and stamina with SS-31. They also reported MOTS-c exposure and perceived improvement when both were used.
Amount, frequency, route and duration could not be confirmed for this account.
Product identity and clinical outcomes were not verified. The combined experience does not establish benefit in ME/CFS or describe the approved Forzinity product.
Read the energy accountHeart symptoms: reported experiences
Dizziness eased after stopping; no benefit on retry
An author described dizziness, lightheadedness and changes in home blood-pressure and heart-rate readings after SS-31. Symptoms eased during a break. A later retry with additional supplements brought neither the same symptoms nor a noticeable benefit.
Reported use in this account
- Product
- Product called SS-31; contents and equivalence to approved elamipretide not verified
- Amount
- 0.5 mg, 1 mg, 2 mg and 3 mg were described on successive initial days
- Frequency
- Daily across the four described initial days
- Route
- Injection; type not stated
- Duration
- Four initial days; later retry duration not stated
Other exposures described: TMG and betaine, named in the later retry
Home measurements and product contents were not verified. The later TMG/betaine exposure prevents interpreting this as a confirmed reaction or a proven remedy; it is not an account of approved Forzinity treatment for Barth syndrome.
Read the original accountSensory changes: reported experiences
Dizziness eased after stopping; no benefit on retry
An author described dizziness, lightheadedness and changes in home blood-pressure and heart-rate readings after SS-31. Symptoms eased during a break. A later retry with additional supplements brought neither the same symptoms nor a noticeable benefit.
Reported use in this account
- Product
- Product called SS-31; contents and equivalence to approved elamipretide not verified
- Amount
- 0.5 mg, 1 mg, 2 mg and 3 mg were described on successive initial days
- Frequency
- Daily across the four described initial days
- Route
- Injection; type not stated
- Duration
- Four initial days; later retry duration not stated
Other exposures described: TMG and betaine, named in the later retry
Home measurements and product contents were not verified. The later TMG/betaine exposure prevents interpreting this as a confirmed reaction or a proven remedy; it is not an account of approved Forzinity treatment for Barth syndrome.
Read the original accountNo clear change: reported experiences
Dizziness eased after stopping; no benefit on retry
An author described dizziness, lightheadedness and changes in home blood-pressure and heart-rate readings after SS-31. Symptoms eased during a break. A later retry with additional supplements brought neither the same symptoms nor a noticeable benefit.
Reported use in this account
- Product
- Product called SS-31; contents and equivalence to approved elamipretide not verified
- Amount
- 0.5 mg, 1 mg, 2 mg and 3 mg were described on successive initial days
- Frequency
- Daily across the four described initial days
- Route
- Injection; type not stated
- Duration
- Four initial days; later retry duration not stated
Other exposures described: TMG and betaine, named in the later retry
Home measurements and product contents were not verified. The later TMG/betaine exposure prevents interpreting this as a confirmed reaction or a proven remedy; it is not an account of approved Forzinity treatment for Barth syndrome.
Read the original accountNo noticeable improvement in a contrasting account
A different commenter in a long-COVID discussion described trying SS-31 without noticing an effect, despite hoping for an energy improvement.
Amount, frequency, route and duration could not be confirmed for this account.
The source described an unverified research product, not confirmed Forzinity treatment. Diagnosis, duration and outcomes were not independently checked.
Read the no-improvement accountApproval status
FDA granted accelerated approval to Forzinity for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kilograms. A post-marketing confirmatory trial is registered, and continued approval may depend on verification of clinical benefit.
Approved uses
- Improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms under the Forzinity label
FDA accelerated approval granted
Elamipretide has FDA accelerated approval for Barth syndrome under the Forzinity label, with post-approval study obligations separate from broader mitochondrial or wellness claims.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether the registered confirmatory trial will verify a patient-centered clinical benefit in Barth syndrome
- Which, if any, other genetically defined mitochondrial disorders benefit
- Long-term safety across broader populations
- Whether laboratory or muscle-energy effects translate into meaningful outcomes outside the approved use
Summary
Forzinity’s accelerated approval is limited to Barth syndrome and relies on an intermediate endpoint. It does not establish general energy or performance benefits.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Forzinity
Current approval scope, accelerated-approval basis, warnings, and adverse reactions.
- fdaFDA: accelerated approval for Barth syndrome
FDA announcement describing the accelerated-approval decision and required confirmatory research.
- clinical trialsClinicalTrials.gov: 4TAZPower
Registered post-marketing confirmatory trial for elamipretide in genetically confirmed Barth syndrome.
- pubmedMMPOWER-3 randomized clinical trial
Phase 3 trial that did not meet its primary walking-distance or fatigue endpoints in primary mitochondrial myopathy.